NotesFAQContact Us
Search Tips
ERIC Number: ED312512
Record Type: Non-Journal
Publication Date: 1988-Nov
Pages: 12
Abstractor: N/A
Reference Count: N/A
New Jersey's Emergency Retrovir Reimbursement Program (ERRP).
Conviser, Richard; And Others
In 1987 Congress made available a one-time, 1-year emergency appropriation to pay for Food and Drug Administration (FDA)-approved life-sustaining drugs for people with Acquired Immune Deficiency Syndrome (AIDS). New Jersey received $1.5 million from this program for antiviral drugs for low-income people with AIDS and AIDS Related Complex lacking other public assistance. The Emergency Retrovir Reimbursement Program (ERRP) provided 175 person-years of Aziodothymidine (AZT). Other sources of funds for AZT in New Jersey included General Assistance, Medicaid, and a Pharmaceutical Assistance Program for the Aged and Disabled (PAAD). The ERRP was arranged to maximize convenience for applicants. With federal approval, income levels for ERRP were substantially higher than for other assistance programs. The program was publicized widely; application processing took 2 weeks. The existing mechanism for reviewing applications for Medicaid and PAAD was used for ERRP. The centralized processing allowed non-qualifying clients to get on other appropriate programs. Approximately 15 percent of those applying for ERRP in its first year were approved for Medicaid or PAAD coverage of AZT. The ERRP also covered co-payment for AZT required of clients with third party coverage who met income criteria. The program made direct payments for AZT to pharmacies. Characteristics of enrollees in the various AZT entitlement programs in New Jersey are described. (Author/ABL)
Publication Type: Reports - Descriptive; Speeches/Meeting Papers
Education Level: N/A
Audience: N/A
Language: English
Sponsor: N/A
Authoring Institution: N/A
Identifiers - Location: New Jersey